NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program

Nurix Therapeutics (NRIX) shares rose 8.7% on Wednesday after the company announced that Sanofi (SNY) has in-licensed exclusive rights to an undisclosed Nurix program aimed at a previously untreatable transcription factor for autoimmune diseases. This undisclosed target plays a key role in regulating inflammation and is separate from the previously revealed STAT6 degrader program, signed between the companies in 2019. The stock is gaining further in the pre-market hours on Thursday.Nurix and Sanofi first es ...